A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Forward-Looking Statements This Annual Report contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements include, but are not limited to: •our ability to successfully commercialize ANKTIVA globally in NMIBC, NSCLC or other indications or any future approved products in the U.S. or internationally; •our ability to obtain incremental approvals for ANKTIVA for new indications, including, without limitation, in BCG-unresponsive NMIBC with papillary tumors and NSCLC from the FDA or clearances or approvals from international regulatory agencies for the treatment of patients with NMIBC, NSCLC or other indications; •potential future uses and applications of ANKTIVA, including as a lymphopenia rescue agent in solid tumors or other indications, and use in cancer vaccines and across mult
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - | - |
| Net Income | -351M | -351M | -414M | -583M | -417M | -347M |
| EPS | $-0.38 | $-0.38 | $-0.62 | $-1.15 | $-1.04 | $-0.89 |
| Free Cash Flow | -309M | -309M | -398M | -397M | -416M | -308M |
| ROIC | -40.3% | -51.0% | -89.9% | -71.8% | -96.9% | -70.4% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | -0.73 | -0.67 | -0.34 | -2.04 | -0.17 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -256M | -256M | -344M | -362M | -351M | -330M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | 0.0% | - | - | - | - | - |
| Shares Outstanding | 925M | 925M | 667M | 507M | 401M | 390M |
ImmunityBio, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
ImmunityBio, Inc. (IBRX) has a 5-year average return on invested capital (ROIC) of -76.0%. This is below average and may indicate limited pricing power.
ImmunityBio, Inc. (IBRX) has a market capitalization of $6.8B. It is classified as a mid-cap stock.
ImmunityBio, Inc. (IBRX) does not currently pay a regular dividend.
ImmunityBio, Inc. (IBRX) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
ImmunityBio, Inc. (IBRX) generated $-309 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
ImmunityBio, Inc. (IBRX) reported earnings per share (EPS) of $-0.38 in its most recent fiscal year.
The Ledger Terminal provides 12 years of financial data for ImmunityBio, Inc. (IBRX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ImmunityBio, Inc. (IBRX) has a book value per share of $-0.54, based on its most recent annual SEC filing.